Gilead Sciences (GILD) released top-line trial data for its Yescarta medication that may allow the company to leapfrog over a rival in the marketing battle over CAR-T therapies.
The preliminary results of a randomized Phase 3 trial showed the treatment — which involves extracting white blood cells and genetically modifying them to attack cancer — prevented the return of large B-cell lymphoma better than the standard of care, which includes chemotherapy and a stem cell transplant. The study examined patients whose initial treatment had failed and given Yescarta as a so-called second-line treatment.
Dubbed ZUMA-7, the study met its primary endpoint of event-free survival and the key secondary endpoint of objective response rate, which refers to the share of patients with a complete or partial response to a drug. An interim analysis of overall survival displayed a trend “favoring” Yescarta, but Gilead said in a press release more analyses are planned. Full results will be released later this year at a medical conference.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
